BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:49 AM
 | 
Jul 21, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ironwood's IW-3718 meets primary in Phase IIb to treat GERD

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said top-line data from a double-blind, U.S. Phase IIb trial in 282 patients with uncontrolled gastroesophageal reflux disease (GERD) showed that twice-daily 1,500 mg oral IW-3718 plus a proton pump inhibitor (PPI) for 8 weeks met the primary endpoint of reducing mean weekly heartburn severity from baseline vs. a PPI alone (58% vs. 46%, p=0.04). Patients received PPI monotherapy or twice-daily 500; 1,000; or 1,500 mg oral...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >